Fundies.
English

Segment disclosures

Company overview

PROVECTUS BIOPHARMACEUTICALS, INC.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 10 retained observations 7 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Clinical Stage Biotechnology Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=PVCT:ClinicalStageBiotechnologySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31336108 USD20260326Open filing evidence
2025-01-01 – 2025-09-30336108 USD20251113Open filing evidence
2025-04-01 – 2025-06-3057480 USD20260813Open filing evidence
2025-01-01 – 2025-06-30336108 USD20260813Open filing evidence
2025-01-01 – 2025-03-31278628 USD20260514Open filing evidence
2024-01-01 – 2024-12-31617140 USD20260326Open filing evidence
2024-07-01 – 2024-09-30109745 USD20251113Open filing evidence
2024-01-01 – 2024-09-30602808 USD20251113Open filing evidence
2024-04-01 – 2024-06-30254991 USD20250814Open filing evidence
2024-01-01 – 2024-06-30493063 USD20250814Open filing evidence